Moderna(MRNA) ZACKS·2025-06-13 22:51Company Performance - Moderna's stock closed at $26.68, showing a decrease of -2.45% from the previous day's closing price, which was less than the S&P 500's daily loss of 1.13% [1] - Over the past month, Moderna's shares increased by 15.65%, outperforming the Medical sector's gain of 3.07% and the S&P 500's gain of 3.55% [1] Financial Projections - The upcoming earnings per share (EPS) for Moderna is projected to be -$2.97, indicating a 10.81% increase from the same quarter last year [2] - Revenue for the same quarter is estimated at $131 million, reflecting a significant decline of 45.64% compared to the equivalent quarter last year [2] - For the full year, the Zacks Consensus Estimates project an EPS of -$9.78 and revenue of $2.08 billion, representing changes of -10.26% and -35.72% from the prior year, respectively [3] Analyst Forecasts - Investors are advised to monitor any recent revisions to analyst forecasts for Moderna, as these revisions indicate the changing nature of near-term business trends [4] - Positive revisions in estimates suggest analysts' confidence in the company's performance and profit potential [4] Zacks Rank and Industry Position - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently places Moderna at a rank of 3 (Hold) [6] - Over the past month, the Zacks Consensus EPS estimate for Moderna has increased by 1.28% [6] - The Medical - Biomedical and Genetics industry, which includes Moderna, has a Zacks Industry Rank of 78, placing it in the top 32% of over 250 industries [7]